Thermo Fisher Scientific Inc. (NYSE: TMO) expects quarterly dividend of $ 0.26
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly dividend on Thursday, July 8, RTT News reports. Investors registered on Wednesday, September 15 will receive a dividend of 0.26 per share from the medical research company on Friday, October 15. This represents a dividend of $ 1.04 on an annualized basis and a return of 0.20%.
Thermo Fisher Scientific has increased its dividend by 46.7% over the past three years and has increased its dividend annually for the past 3 years. Thermo Fisher Scientific has a dividend payout ratio of 4.7%, indicating that its dividend is sufficiently covered by earnings. Research analysts expect Thermo Fisher Scientific to earn $ 19.51 per share next year, which means the company should continue to be able to cover its annual dividend of $ 1.04 with a rate expected future distribution of 5.3%.
TMO stock traded down $ 4.11 during Thursday’s session, reaching $ 518.61. 1,383,972 shares of the company were traded for an average volume of 1,797,097. Thermo Fisher Scientific has a 12-month low of $ 375.14 and a 12-month high of $ 532.57. The company’s 50-day moving average price is $ 472.89. The company has a market cap of $ 203.83 billion, a price-to-earnings ratio of 26.32, a price-to-earnings-growth ratio of 1.20, and a beta of 0.76. The company has a quick ratio of 1.91, a current ratio of 2.53, and a debt ratio of 0.53.
Thermo Fisher Scientific (NYSE: TMO) last released its quarterly earnings data on Thursday, April 29. The medical research company reported earnings per share of $ 7.21 for the quarter, beating analyst consensus estimates of $ 6.69 by $ 0.52. The company posted revenue of $ 9.91 billion for the quarter, compared to a consensus estimate of $ 9.69 billion. Thermo Fisher Scientific reported 28.95% return on equity and 22.08% net margin. The company’s revenue for the quarter increased 59.0% from the same quarter last year. In the same quarter of last year, the company made earnings per share of $ 2.94. Equity research analysts expect Thermo Fisher Scientific to post earnings per share of 22.02 for the current fiscal year.
In other news from Thermo Fisher Scientific, Executive Vice President Michel Lagarde sold 34,168 shares of the company in a transaction dated Friday, May 7. The stock was sold for an average price of $ 472.60, for a total trade of $ 16,147,796.80. Following the sale, the Executive Vice President now owns 52,629 shares of the company, valued at approximately $ 24,872,465.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.44% of the shares are currently owned by insiders.
Several brokerage firms weighed on TMO. The Goldman Sachs group lowered its price target on Thermo Fisher Scientific from $ 590.00 to $ 530.00 and set a “buy” rating for the company in a report released on Tuesday, June 15. They noted that the move was an appraisal call. Robert W. Baird raised his price target on Thermo Fisher Scientific from $ 545.00 to $ 550.00 and rated the stock as “outperforming” in a research note on Wednesday, June 23. KeyCorp upgraded Thermo Fisher Scientific from an “industry weight” rating to an “overweight” rating and set a price target of $ 520.00 for the company in a research note on Thursday, March 18. Evercore ISI raised its price target on Thermo Fisher Scientific from $ 525.00 to $ 540.00 and rated the stock as “outperforming” in a research note on Friday April 16. Finally, the UBS Group lowered its price target on Thermo Fisher Scientific from $ 588.00 to $ 560.00 and set a “buy” note for the company in a research note on Monday, March 29. Three investment analysts gave the stock a conservation rating and eighteen gave the company’s stock a buy rating. The company currently has an average “Buy” rating and a consensus price target of $ 533.80.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides solutions for life sciences, analytical instrumentation, specialty diagnostics, and laboratory products and services around the world. The Life Sciences Solutions segment of the company offers reagents, instruments and consumables for biological and medical research, drug and vaccine discovery and production, as well as the diagnosis of infections and diseases in the pharmaceutical industry, biotechnology, agriculture, clinical, health, academia and public procurement.
Recommended Story: What Are the Different Types of Coverage Ratios?
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: How to calculate return on equity (ROE)?
7 stocks that still have potential for investors to buy
It can be fun to invest in certain speculative stocks. But it goes without saying that these stocks don’t have to be the bulk of your portfolio. In fact, it’s important to find a few good stocks that form the basis of your portfolio. These are dynamic stocks that are in a strong uptrend.
One way to find these stocks is to look at the most active stocks (or volume leaders). The shares of these companies are among the most traded or have the highest volume of shares traded on any given trading day.
Any action can break this list from time to time (for example, when there is new business news). However, stocks tend to end up on this list consistently, which is worth watching. This is because this listing indicates that there is pressure among investors to buy or sell the stock. And that makes the decision of an investor very simple.
And that’s why we created this special presentation. The stocks on this list are some of the most actively traded stocks on the market today. They also share a similar quality. They are coming off a good year in 2020 and seem to be showing some consolidation for another head start.
Check out the “7 stocks that still have potential for investors to buy”.